We thus propose HectD3 as a “dual pathway” inhibitor for the prevention and/or therapy of cardiac hypertrophy and heart failure, e.g. utilizing AAV-mediated gene transfer. This evidence concerns the gene HECTD3 and cardiac hypertrophy.